Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy
about
Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent CancersPromising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer.The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeuticsBiomarkers for glioma immunotherapy: the next generationGlypican-3 Targeting Immunotoxins for the Treatment of Liver CancerAdvances in anticancer immunotoxin therapyIdentification of novel tumor-associated cell surface sialoglycoproteins in human glioblastoma tumors using quantitative proteomicsEpidermal growth factor receptor and variant III targeted immunotherapy.CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats.A bivalent recombinant immunotoxin with high potency against tumors with EGFR and EGFRvIII expression.Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas.Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells.Immunotoxin Therapy for Lung Cancer.EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery.ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma.Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial.Recent progress in protein-protein interaction study for EGFR-targeted therapeutics.A novel immunotoxin - rCCK8PE38 targeting of CCK-R overexpressed colon cancers.EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastomaTargeting Malignant Brain Tumors with Antibodies.EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.Elevated expression of podoplanin and its clinicopathological, prognostic, and therapeutic values in squamous non-small cell lung cancer.Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers.
P2860
Q26751473-2B369438-F0FB-4E6F-A197-3C2FAC1BCE1DQ26778701-2A69199F-B48E-41C7-A119-630C4AE97FCEQ26795601-E778DAEE-8F9B-48E0-9809-69DF4FB48A88Q26825496-CC2D1DE2-B6C5-48FE-BFF4-CAD96C5765F1Q28077270-3994BA67-491A-469B-BC73-CE18F0D8983BQ28085551-6F97435D-CB90-4EFB-9EF0-FB4E19DF54FCQ28544645-DBD3E5B0-2CCD-48BA-BA96-1A7B6892C8F6Q34391942-5A3A086A-FD12-4844-9BCA-BB10E12352DFQ35834087-1FE3F3FB-DFCA-4AA9-A90E-C07BA29BCA43Q36678043-4903B195-621C-4CA6-81DD-971577FEC87DQ36843748-D0EBB784-A553-49F8-91AB-98DEC1944178Q37364358-94B32A90-F743-45BA-8A34-22CB1DF881E4Q37376200-BEDC89F1-718A-4276-939D-B9B6055EC49AQ37684156-7D833532-E4F2-41CB-A61F-6934333C92E1Q37686698-709F7D99-10CE-4600-9060-8AE54547E36CQ38398440-D64BAA18-EBAB-4C3D-B9FF-5397857BA0BCQ38694765-19EAF264-460A-4F26-9FC6-ABCFF67A42ABQ38724406-0D9EDB86-AD1F-4C1B-94E8-450741C9C4A1Q38899428-C9925055-0C71-4A0C-869C-20C182D1DB36Q38910559-CA0F4E3E-4DF7-440E-8B4C-0A6E98EBA71BQ40089704-2D08E8DE-01C5-4ED9-BA80-4BD10BDE9511Q41022992-ADA1496B-A367-488E-A7DA-30DD3793DCB5Q41033340-18C7CE6A-B445-40DF-8046-87250D30883BQ41841115-08D47E7F-1A0F-41BA-B784-72B3FA6870F1Q42267793-571D71DB-B2F7-4A1D-9D93-068EDD932762Q48014727-B259D05F-2C01-4DF7-BF02-472EA3C7D3C1Q54964718-D1A3632F-9494-48C2-828C-F12CCC8F16BCQ55363919-4839E0C7-6424-4173-949E-64F8897315DFQ55460776-BD42847C-F71B-4433-AF9D-DDE473A98374
P2860
Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Construction of an immunotoxin ...... FRvIII for brain tumor therapy
@en
Construction of an immunotoxin ...... RvIII for brain tumor therapy.
@nl
type
label
Construction of an immunotoxin ...... FRvIII for brain tumor therapy
@en
Construction of an immunotoxin ...... RvIII for brain tumor therapy.
@nl
prefLabel
Construction of an immunotoxin ...... FRvIII for brain tumor therapy
@en
Construction of an immunotoxin ...... RvIII for brain tumor therapy.
@nl
P2093
P2860
P1476
Construction of an immunotoxin ...... FRvIII for brain tumor therapy
@en
P2093
Carol J Wikstrand
Charles N Pegram
Chien-Tsun Kuan
Hailan Piao
Ira H Pastan
Scott E Szafranski
Stephen T Keir
Vidyalakshmi Chandramohan
P2860
P304
P356
10.1158/1078-0432.CCR-12-3891
P407
P577
2013-07-15T00:00:00Z